Literature DB >> 20821206

On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer.

Paolo Zanotti-Fregonara, Elif Hindié.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20821206     DOI： 10.1007/s00259-010-1608-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  15 in total

Review 1.  ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

Authors:  Daniele Barbaro; Frederik A Verburg; Markus Luster; Christoph Reiners; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

2.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

5.  Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.

Authors:  R Michael Tuttle; Norma Lopez; Rebecca Leboeuf; Shaye M Minkowitz; Ravinder Grewal; Matvey Brokhin; Gal Omry; Steve Larson
Journal:  Thyroid       Date:  2010-03       Impact factor: 6.568

6.  Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.

Authors:  Christian Pötzi; Abbas Moameni; Georgios Karanikas; Josef Preitfellner; Alexander Becherer; Christian Pirich; Robert Dudczak
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

Review 7.  rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

Authors:  Markus Luster; Francesco Lippi; Barbara Jarzab; Petros Perros; Michael Lassmann; Christoph Reiners; Furio Pacini
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

8.  Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.

Authors:  V Lazar; J M Bidart; B Caillou; C Mahé; L Lacroix; S Filetti; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

9.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

10.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.

Authors:  Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285
View more
  3 in total

Review 1.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

2.  Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Anneke C Muller Kobold; Bruce H R Wolffenbuttel; John T M Plukker; Peter H Bisschop; John M de Klerk; Imad Al Younis; Paul Lips; Jan W Smit; Adrienne H Brouwers; Thera P Links
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 3.  Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.

Authors:  Einat Slonimsky; Mark Tulchinsky
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.